These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 4985431)

  • 21. Infective virus substructure from vesicular stomatitis virus.
    Brown F; Cartwright B; Crick J; Smale CJ
    J Virol; 1967 Apr; 1(2):368-73. PubMed ID: 4318952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on Chikungunya virus. II. Purification of mouse brain virus.
    Igarashi A; Fukai K; Tuchinda P
    Biken J; 1967 Dec; 10(4):189-94. PubMed ID: 5591504
    [No Abstract]   [Full Text] [Related]  

  • 23. [Use of tween 80 and ether for the preparation of diagnostic hemagglutinating antigens from group A and B Arboviruses].
    Wróblewska-Mularczykowa ; Dobrzyński L
    Med Dosw Mikrobiol; 1969; 21(1):71-5. PubMed ID: 5789985
    [No Abstract]   [Full Text] [Related]  

  • 24. Chloroform inactivation of reovirus hemagglutinins.
    Rozee KR; Leers WD
    Can Med Assoc J; 1967 Mar; 96(10):597-9. PubMed ID: 4960135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physical and biological properties of dengue-2 virus and associated antigens.
    Smith TJ; Brandt WE; Swanson JL; McCown JM; Buescher EL
    J Virol; 1970 Apr; 5(4):524-32. PubMed ID: 4195055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the purification of virus antigens on the production of specific complement-fixing antibodies.
    Engler R; Keairnes P
    Appl Microbiol; 1971 Apr; 21(4):653-6. PubMed ID: 4995851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of rubella complement-fixing antigens.
    Schmidt NJ; Lennette EH
    Appl Microbiol; 1967 Jul; 15(4):916-20. PubMed ID: 6049308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation of inactivated vaccines against alphaviruses using Semliki Forest virus-white mouse as a model. II. Evaluation of formalin-inactivated vaccines treated with tri(n-butyl)phosphate and-or saponin and properties of the inactivated virus.
    Mussgay M; Weiland E
    Intervirology; 1973; 1(4):269-77. PubMed ID: 4775475
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemagglutination by equine infectious anemia virus.
    Sentsui H; Kono Y
    Infect Immun; 1976 Aug; 14(2):325-31. PubMed ID: 9361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural components of chikungunya virus.
    Igarashi A; Fukuoka T; Nithiuthai P; Hsu LC; Fukai K
    Biken J; 1970 Jun; 13(2):93-110. PubMed ID: 5469580
    [No Abstract]   [Full Text] [Related]  

  • 32. Characteristics of Venezuelan equine encephalomyelitis virus ribonucleoprotein.
    Uryvayev LV; Zhdanov VM; Yershov FI; Bykovsky AF
    Arch Gesamte Virusforsch; 1971; 33(3):281-7. PubMed ID: 5165328
    [No Abstract]   [Full Text] [Related]  

  • 33. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
    DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
    J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The tween-ether treated hemagglutinin of parainfluenza 2 virus.
    John T; Askin P; Fulginiti VA
    Arch Gesamte Virusforsch; 1967; 22(3):381-7. PubMed ID: 4300619
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification of measles virus-specific hemolysis-inihibiting antibodies separate from hemagglutination-inhibiting antibodies.
    Norrby E; Gollmar Y
    Infect Immun; 1975 Feb; 11(2):231-9. PubMed ID: 803467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inactivated influenza vaccine efficacy: diminished antigenicity of split-product vaccines in mice.
    Barry DW; Staton E; Mayner RE
    Infect Immun; 1974 Dec; 10(6):1329-36. PubMed ID: 4435958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus associated viruses.
    Hoggan MD
    Prog Med Virol; 1970; 12():211-39. PubMed ID: 4991627
    [No Abstract]   [Full Text] [Related]  

  • 39. Dengue virions and antigens in brain and serum of infected mice.
    Brandt WE; Cardiff RD; Russell PK
    J Virol; 1970 Oct; 6(4):500-6. PubMed ID: 5497897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological surveys of arbovirus infections in South-East Asia, with special reference to dengue, chikungunya, and Kyasanur Forest disease.
    Rao TR
    Bull World Health Organ; 1971; 44(5):585-91. PubMed ID: 4400821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.